Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 100 of 2293 matching drugs for KDR — including drugs targeting any of its 142 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
sunitinib KDR Direct yes 5
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab KDR Direct 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) KDR Direct 4
ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine KDR Direct 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib KDR Direct 3
pembrolizumab, belzutifan, lenvatinib KDR Direct 3
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan KDR Direct 2
avelumab, lorlatanib, talazoparib, pemetrexed, axitinib, cmp 001, utomilumab, pf04518600 KDR Direct 2
cabozantinib KDR Direct yes 2
cabozantinib, atezolizumab, cabozantinib, cabozantinib KDR Direct 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib KDR Direct 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a KDR Direct 2
lenvatinib, pembrolizumab KDR Direct 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate KDR Direct 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a KDR Direct 2
nintedanib KDR Direct yes 2
nintedanib, pembrolizumab KDR Direct 2
pazopanib KDR Direct yes 2
pembrolizumab, lenvatinib KDR Direct 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu KDR Direct 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin KDR Direct 2
ramucirumab KDR Direct yes 2
ramucirumab, paclitaxel KDR Direct 2
regorafenib KDR Direct yes 2
regorafenib, laboratory biomarker analysis KDR Direct 2
sorafenib, administered orally, ct/mri KDR Direct 2
trastuzumab, abt-806, bemarituzumab, ramucirumab, nivolumab, standard cytotherapy KDR Direct 2
5-fluorouracil (5-fu), leucovorin, oxaliplatin, atezolizumab, cobimetinib, ramucirumab, paclitaxel, pegylated recombinant human hyaluronidase (pegph20), bl-8040, linagliptin, atezolizumab, cobimetinib, cisplatin, tiragolumab, 5-fluorouracil (5-fu) KDR Direct 1
agent-797, botensilimab, balstilimab, ramucirumab, paclitaxel KDR Direct 1
atezolizumab, cabozantinib KDR Direct 1
atezolizumab, tivozanib KDR Direct 1
axitinib KDR Direct yes 1
axitinib, avelumab KDR Direct 1
axitinib, axitinib plus lomustine KDR Direct 1
bemarituzumab, paclitaxel, ramucirumab, bemarituzumab, irinotecan, bemarituzumab, trifluridine/tipiracil KDR Direct 1
bevacizumab, cediranib, cediranib maleate, olaparib KDR Direct 1
biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging, sunitinib KDR Direct 1
biopsy, biospecimen collection, computed tomography, erdafitinib, magnetic resonance imaging KDR Direct 1
biospecimen collection, computed tomography, magnetic resonance imaging, nivolumab, paclitaxel, questionnaire administration, ramucirumab KDR Direct 1
biospecimen collection, erdafitinib, magnetic resonance imaging, optical coherence tomography KDR Direct 1
byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab KDR Direct 1
cabozantinib, durvalumab, tremelimumab KDR Direct 1
cabozantinib, nivolumab KDR Direct 1
cabozantinib, pembrolizumab KDR Direct 1
capecitabine, medi4736 (durvalumab), trastuzumab, rucaparib, ramucirumab KDR Direct 1
cediranib, cediranib, lomustine chemotherapy, placebo cediranib KDR Direct 1
cediranib, lomustine KDR Direct 1
cisplatin, pemetrexed disodium, sorafenib KDR Direct 1
crenolanib, ramucirumab, paclitaxel KDR Direct 1
durvalumab, olaparib, cediranib KDR Direct 1
erdafitinib KDR Direct 1
everolimus, sorafenib KDR Direct 1
everolimus, vatalanib, pharmacological study, laboratory biomarker analysis, dynamic contrast-enhanced magnetic resonance imaging, ultrasound imaging KDR Direct 1
evorpacept (alx148), trastuzumab, ramucirumab, paclitaxel KDR Direct 1
fruquintinib, sintilimab KDR Direct 1
fruquintinib, tislelizumab, radiotherapy KDR Direct 1
gemcitabine, erlotinib, sorafenib KDR Direct 1
gemcitabine, placebo, sorafenib KDR Direct 1
gemcitabine, sorafenib, radiotherapy KDR Direct 1
gemcitabine, sorafenib, vorinostat, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, rosettesep, depfff KDR Direct 1
gemcitabine, sunitinib KDR Direct 1
h101, tislelizumab, lenvatinib KDR Direct 1
hydroxyurea, imatinib mesylate, vatalanib KDR Direct 1
imt-009, fruquintinib KDR Direct 1
irinotecan, ramucirumab, blood for angiome profiling, blood for cfdna KDR Direct 1
ko-2806, cabozantinib, adagrasib KDR Direct 1
lenalidomide, bevacizumab, sorafenib, temsirolimus, lenalidomide, oxaliplatin, leucovorin, 5-fluorouracil KDR Direct 1
lenvatinib, bevacizumab KDR Direct 1
nivolumab, cabozantinib KDR Direct 1
olaparib, ramucirumab KDR Direct 1
olaratumab, ramucirumab KDR Direct 1
oxaliplatin, sorafenib KDR Direct 1
paclitaxel, irinotecan, pembrolizumab, mk-4830, lenvatinib, sacituzumab tirumotecan, antihistamine, h2 receptor antagonist, acetaminophen (or equivalent), dexamethasone (or equivalent) KDR Direct 1
paclitaxel, quality-of-life assessment, ramucirumab, trifluridine and tipiracil hydrochloride KDR Direct 1
pazopanib, 5-fu, oxaliplatin, leukovorin (flo) KDR Direct 1
pazopanib, lapatinib KDR Direct 1
pazopanib, placebo KDR Direct 1
pegilodecakin, paclitaxel or docetaxel and carboplatin or cisplatin, folfox (oxaliplatin/leucovorin/5-fluorouracil), gemcitabine/nab-paclitaxel, capecitabine, pazopanib, pembrolizumab, paclitaxel, nivolumab, gemcitabine/carboplatin KDR Direct 1
pembrolizumab, coformulation favezelimab/pembrolizumab, mk-4830, lenvatinib, irinotecan, paclitaxel KDR Direct 1
pembrolizumab, lenvatinib, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, paclitaxel KDR Direct 1
ponatinib KDR Direct 1
radiation therapy, temozolomide, sorafenib KDR Direct 1
ramucirumab, capecitabine, cisplatin, placebo, fluorouracil KDR Direct 1
ramucirumab, paclitaxel, mk-2870 KDR Direct 1
ramucirumab, paclitaxel, placebo KDR Direct 1
ramucirumab, placebo, oxaliplatin, leucovorin, 5-fluorouracil KDR Direct 1
ramucirumab, placebo, s-1, oxaliplatin, paclitaxel KDR Direct 1
regorafenib, lomustine KDR Direct 1
regorafenib, nivolumab, capeox, folfox regimen KDR Direct 1
regorafenib, nivolumab, docetaxel, paclitaxel, irinotecan, trifluridine/tipracil KDR Direct 1
regorafenib, temozolomide KDR Direct 1
rucaparib, ramucirumab, nivolumab KDR Direct 1
ryz101, everolimus, sunitinib, octreotide, lanreotide KDR Direct 1
semaxanib KDR Direct 1
serplulimab, lenvatinib, paclitaxel/paclitaxel-albumin/paclitaxel liposome KDR Direct 1
sorafenib KDR Direct yes 1
sorafenib, erlotinb KDR Direct 1
sorafenib, rad001 KDR Direct 1
sorafenib, radiofrequency ablation (rfa) or surgery, everolimus, lanreotide KDR Direct 1
sunitinib, placebo KDR Direct 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.